BLR&D Research Career Scientist Award Application

BLR

• 批准号: 10047294
• 负责人: HUIPING Rose ZHOU
• 金额: --
• 依托单位: VA VETERANS ADMINISTRATION HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-10-01 至 2023-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10047294
• 关键词: Acids; Address; Alcoholic Fatty Liver; Alternative Medicine; Animal Model; Animals; Archives; Award; Berberine; Bile Acids; Cholangiocarcinoma; Cholestasis; Clinical; Clinical Trials; Communication; Communities; Development; Disease Progression; Estrogens; Ethics; Event; FDA approved; Faculty; Foundations; Funding; Future; Gastroenterology; Gastrointestinal Injury; Genetic; Glycolates; Goals; Grant; H19 gene; HIV; HIV Protease Inhibitors; Health; Healthcare; Hepatic; Hepatocyte; Hepatology; Homeostasis; Immunology; Internal Medicine; Knockout Mice; Laboratories; Link; Lipids; Liver diseases; Mediating; Medical Research; Medical center; Medicine; Messenger RNA; Metabolic Diseases; Microbiology; Mission; Molecular; Natural Products; Pathogenesis; Pathologic; Peer Review; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Physiological; Plants; Play; Positioning Attribute; Publishing; RNA-Binding Proteins; Reporting; Research; Research Personnel; Research Project Grants; Role; Scientist; Services; Signal Pathway; Sphingolipids; Taurine Cholate; Techniques; Therapeutic; Therapeutic Agents; Therapeutic Effect; Tissues; Toxicology; United States National Institutes of Health; Universities; Untranslated RNA; Veterans; Virginia; Work; base; career; cholestatic liver disease; clinical development; effective therapy; endoplasmic reticulum stress; extracellular; inorganic phosphate; lipid metabolism; liver injury; medical schools; military veteran; non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; novel; novel therapeutic intervention; novel therapeutics; patient population; prevent; professor; programs; protective effect; receptor; research study; side effect; therapeutically effective

AIMS: The goal of this application is to apply for Research Career Scientist (RCS) Award and to support Dr. Huiping Zhou’s VA research program. NOMINEE: Dr. Zhou has held a VA Research Chemist position since 2008, and she also holds the title of Tenured Professor in the Department of Microbiology and Immunology at Virginia Commonwealth University School of Medicine in Richmond, Virginia. Dr. Zhou’s research program has been continuously funded by VA MERIT Review Awards, NIH R01 grants, several local foundations and pharmaceutical companies since she established her independent research program in 2004. Dr. Zhou has made significant contributions to scientific research fields related to liver injury and metabolic diseases throughout her career, and published more than 100 peer- reviewed original research articles that have created more than 6000 citations. In addition, Dr. Zhou acts as a co-investigator in several VA-sponsored research projects. Research: Studies in Dr. Zhou’s laboratory are to investigate the mechanisms underlying drug- induced liver injury and the role of bile acid-mediated signaling pathways in hepatic lipid metabolism under physiological and pathological conditions, and to further search for new and more effective therapies to prevent and treat metabolic diseases. Disruption of hepatic bile acid homeostasis occur commonly in various pathological states such as non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease (ALD), cholestatic liver diseases as well as drug- induced liver injury. Since the exact mechanisms underlying bile acid-mediated liver injury and metabolic diseases are still obscure, effective therapeutics are limited. Dr. Zhou’s research is highly focused on identification of novel cellular/molecular mechanisms involved in disease progression of NAFLD, ALD and cholestatic liver diseases. Dr. Zhou’s research employs the stat- of-the-art techniques, including isolation and culture of various hepatic cells, examine specific messenger RNA (mRNA), non-coding RNA (ncRNA), mRNA/ncRNA/RNA –binding proteins (RBP) interactions and extracellular vehicles-mediated communications. Dr. Zhou’s group has established animal models for NAFLD/NASH, ALD, and cholestasis. Her group has also extensively used genetic modified animals including tissue-specific knockout mice. The overreaching goal of Dr. Zhou’s research program is to elucidate the cellular/molecular mechanisms that govern hepatic lipid homeostasis and to create a fundamental base for development of new therapeutics for various liver diseases. IMPACT: Dr. Zhou’s research program directly addresses an important health issue relevant to the VA mission, since NAFLD/NASH, ALD and cholestatic liver diseases occur commonly in our VA patient population. Dr. Zhou is also actively collaborates a number of investigators in the Research service of the McGuire VA Medical Center. Her expertise and academic activity help promoting VAMHCS research.

目的：本申请的目的是申请研究职业科学家（RCS）奖并 支持周惠平博士的VA研究项目。 提名人：周博士自 2008 年起担任 VA 研究化学家职位，她还担任 弗吉尼亚微生物学和免疫学系终身教授称号 弗吉尼亚州里士满联邦大学医学院周博士的研究。 该计划一直受到 VA MERIT 评审奖、NIH R01 赠款、多项资助 自从她建立独立研究以来，当地基金会和制药公司 2004年获得博士学位。周博士在相关科研领域做出了重大贡献 在她的整个职业生涯中，她一直致力于肝损伤和代谢疾病的研究，并发表了 100 多篇同行文章 此外，Dr. 还审阅了被引用次数超过 6000 次的原创研究文章。 周博士是多个 VA 资助的研究项目的联合研究员。 研究：周博士实验室的研究旨在调查药物的潜在机制 诱导性肝损伤及胆汁酸介导的信号通路在肝脂质中的作用 生理和病理条件下的代谢，并进一步寻找新的和 预防和治疗肝胆汁酸破坏的更有效疗法。 稳态常见于非酒精性脂肪肝等多种病理状态 疾病（NAFLD）、酒精性脂肪肝病（ALD）、胆汁淤积性肝病以及药物性肝病 由于胆汁酸介导的肝损伤的确切机制和 代谢性疾病仍不清楚，有效的治疗方法周博士的研究有限。 高度关注疾病相关的新型细胞/分子机制的识别 周博士的研究采用了非酒精性脂肪性肝病（NAFLD）、酒精性肝病（ALD）和胆汁淤积性肝病的进展。 最先进的技术，包括分离和培养各种肝细胞，检查特定的 信使 RNA (mRNA)、非编码 RNA (ncRNA)、mRNA/ncRNA/RNA 结合蛋白 (RBP) 周博士的团队研究了相互作用和细胞外载体介导的通讯。 她的团队还建立了 NAFLD/NASH、ALD 和胆汁淤积的动物模型。 一般使用的转基因动物包括组织特异性基因敲除小鼠。 周博士研究计划的终极目标是阐明细胞/分子 控制肝脂质稳态的机制并为 开发治疗各种肝脏疾病的新疗法。 影响：周博士的研究项目直接解决了与以下疾病相关的重要健康问题： VA 使命，因为 NAFLD/NASH、ALD 和胆汁淤积性肝病在我们的国家中很常见 周博士还积极与 VA 患者群体中的许多研究人员合作。 麦奎尔退伍军人医疗中心的研究服务她的专业知识和学术活动提供了帮助。 促进 VAMHCS 研究。